Claims for Patent: 5,776,456

Summary for Patent: 5,776,456

Title:	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Abstract:	Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Inventor(s):	Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Olivenhain, CA), Leonard; John E. (Encinitas, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Sante Fe, CA)
Assignee:	IDEC Pharmaceuticals Corporation (San Diego, CA)
Application Number:	08/476,275
Patent Claims:	1. A method for treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of immunologically active chimeric anti-CD20 antibody to a human, said antibody being derived from a transfectoma comprising anti-CD20 in TCAE 8, ATCC deposit number 69119. 2. The method of claim 1 wherein the amount of said antibody administered to said human is between about 0.001 to about 30 milligrams of antibody per kilogram body weight of said human ("mg/kg"). 3. The method of claim 1 further comprising the step of administering a second therapeutically effective amount of said chimeric anti-CD20 antibody to said human. 4. The method of claim 3 wherein said additional administration of said antibody to said human occurs within about seven days of said first administration of said antibody to said human. 5. A method for the treatment of B cell lymphoma comprising the steps of: 1) administering, at a first administration period, an immunologically active chimeric anti-CD20 antibody to a human, wherein said chimeric anti-CD20 antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as ATCC deposit number 69119; and, 2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human. 6. The method of claim 5 wherein said radiolabeled anti-CD20 antibody comprises a monoclonal antibody secreted from a hybridoma identified by American Type Culture Collection deposit number HB 11388. 7. A method for the treatment of B cell lymphoma comprising the steps of: 1) administering to a human having B cell lymphoma, at a first administration period, a first therapeutically effective amount of immunologically active chimeric anti-CD20 antibody produced by a transfectoma comprising anti-CD20 in TCAE8, ATCC deposit number 69119; 2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody; and 3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody. 8. The method of claim 7, wherein said first, second and third therapeutically effective amount of said antibody is between 0.001 mg/kg to about 30 mg/kg. 9. The method of claim 7, wherein said second administration period is within about seven days of said first administration period. 10. The method of claim 7, wherein said third administration period is within about fourteen days of said first administration period. 11. The method of claim 1, which further includes the administration of at least one chemotherapeutic agent. 12. The method of claim 11, wherein the chemotherapeutic agent is administered after the administration of said immunologically active chimeric anti-CD20 antibody. 13. The method of claim 11, wherein the chemotherapeutic agent is administered prior to the administration of said immunologically active chimeric anti-CD20 antibody. 14. The method of claim 11, wherein the chemotherapeutic agents are selected from the group consisting of cyclophosphamide doxorubicin, vincristine and prednisone.

Details for Patent 5,776,456

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002		2015-07-07

International Patent Family for US Patent 5,776,456

Country	Patent Number	Estimated Expiration
Austria	139900
Austria	196606
Austria	421335
Austria	431158
Australia	5603294